Bdd Study Patient Consent Form

This is a request for your participation in my research focusing on the effect of cognitive behavioural therapy (CBT) in conjunction with medication, in the treatment of Body Dysmorphic Disorder (BDD). The purpose of this study is to assess if both treatment strategies, delivered concurrently, are more successful in treating BDD. Within psychology research, there has been ample evidence documenting the efficacy of both CBT and the drug fluoxetine in treating BDD, but there no studies have assessed the effectiveness of both treatments in conjunction. This research can potentially provide evidence for a novel approach to BDD treatment. If you are an adult with a formal diagnosis of BDD and are not currently receiving any treatment, you qualify for participation. Participation will entail a total of 24 2-hour weekly sessions, which will be scheduled at a time convenient to you, and will be held in our University clinic. During the session, you will receive either CBT followed by a weekly dose of fluxotine, CBT followed by a placebo “sugar pill”, or CBT alone. I will be measuring the effects of the treatments using a scoring system based on the Yale Brown Obsessive Compulsive Scale (modified for BDD). This is a 30 minute questionnaire which you will be asked to fill out prior to the start of treatment, and following the 24 week treatment period. All information will remain confidential, and the research material will only be shared amongst the physicians and therapists. Participants can choose to withdraw at any time, at which point any information previously obtained will be destroyed.

Information on the drug Fluoxetine (Prozac) and potential side-effects
The drug with which you may be treated is called Fluoxetine (more commonly known as Prozac). It is an FDA approved drug that has been widely used in treating major depression, obsessive-compulsive disorder (as well as BDD), bulimia nervosa, and, panic disorder. Prozac is manufactured by Eli Lilly and